Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Farmak Tafamidis Meglumine

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-08-25

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Tafamidis Meglumine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 18,998Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Pfizer Canada ULC

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Pfizer Canada ULC

    Tafamidis Meglumine
    arrow
    Peptide Process CMC
    Not Confirmed

    Pfizer Canada ULC

    Country
    arrow
    Peptide Process CMC
    Not Confirmed

    Patent Expiration Date : 2023-12-19

    Date Granted : 2013-03-12

    Tafamidis Meglumine

    Brand Name : VYNDAQEL

    Patent Number : 2510455

    Filing Date : 2003-12-19

    Strength per Unit : 20mg

    Dosage Form : CAPSULE

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2023-12-19

    Date Granted : 2013-03-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF